Indication & Dosage |
| |
| |
| Oral |
| CONGENITAL ICTHYOSIS |
| Adult:
Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods. |
| |
| Oral |
| DARIER'S DISEASE |
| Child:
500 mcg/kg/day. Max dose: 35 mg/day. |
| |
| Oral |
| DARIER'S DISEASE |
| Adult:
Initially, 10 mg daily for 2-4 wk. Max: 50 mg/day |
| |
| Oral |
| CONGENITAL ICTHYOSIS |
| Child:
500 mcg/kg/day. Max: 35 mg daily. |
| |
| Oral |
| SEVERE LICHEN PLANUS |
| Adult:
Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods. |
| |
| Oral |
| SEVERE LICHEN PLANUS |
| Child:
500 mcg/kg/day. Max: 35 mg daily. |
| |
| Oral |
| SEVERE PSORIASIS |
| Adult:
Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods. |
| |
| Oral |
| SEVERE PSORIASIS |
| Child:
500 mcg/kg/day. Max: 35 mg daily. |
|
| |
|
| Administration |
Should be taken with food. (Take w/ main meals or w/ a glass of milk.) |
| |
|
| Precautions |
Female patients to avoid alcohol during and 2 mth after treatment. Avoid blood donation during therapy or at least 1-3 yr after stopping therapy. Children. Radiographic treatment for prolonged therapy. Therapy should not last >6 mth. Monitor plasma lipid and glucose levels (especially diabetics) regularly. Monitor LFTs. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Dryness of mucous membranes and skin; conjunctivitis, dry sore mouth; ophth disturbances; raised lipid level, pancreatitis; sticky skin, dermatitis. Severe headache; GI disturbances; dermatologic reactions, oedema, paronychia, granulomatous lesions, bullous eruptions; reversible hair thinning and alopoecia; CNS disturbances; sweating; taste disturbance, gingivitis; benign intracranial hypertension; photosensitivity; skeletal hyperostosis; extraosseous calcification; premature epiphyseal closure in child. |
| |
|
| Adverse Drug Reactions |
Phototoxicity, jaundice, hepatitis and hepatotoxity. |
| |
|
| Interactions |
Concomitant use with keratolytics or high dose vitamin A. Reduces anticoagulant effect of coumarins e.g. warfarin. Concomitant use of microdised progestin oral contraceptives. Concomitant use of methotrexate can potentiate hepatotoxicty. Concomitant use with tetracycline. |
| |
|
